N. Russell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
N. Russell has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
C. D. Canizo
Aarhus University Aarhus Denmark
1 shared publication- Hans Erik Johnsen
Department of Haematology, Aalborg University Hospital, Aalborg, Denmark
1 shared publication J. Schubert
Saarland University Medical School, Homburg/Saar, Germany
1 shared publicationM. Boogaerts
University Hospital Gasthuisberg, Leuven, Belgium
1 shared publicationN. Baker
Amgen Ltd, Cambridge, UK
1 shared publicationN. Schmitz
Asklepios Klinik St. Georg, Hamburg, Germany
1 shared publication
Latest Publications
- Open Access
- 1 March 2008
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 93 (3) , 405-412
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy
Background Growth factors are frequently used to aid peripheral blood progenitor cell mobilization from bone marrow. This phase 2 study examined the efficacy and safety of pegfilgrastim for mobilizing peripheral blood progenitors cells for autologous transplantation. Design and Methods Patients with non-Hodgkin’s lymphoma received one cycle of mobilizing chemotherapy (ifosfamide, carboplatin and etoposide, ICE). Twenty-four hours later they were randomized, double-blind, to receive a single dose of pegfilgrastim 6 mg or 12 mg, or filgrastim 5 μg/kg/day (until the end of leukapheresis). Following leukapheresis (collection phase), patients rested or received one or two ‘salvage’ cycles of ICE. High-dose BEAM chemotherapy was then given before peripheral blood progenitor cell transplantation. The primary end-point was the patients’ mean yield of CD34+ cells/kg during the collection phase. Results Ninety patients were randomized and received a study drug; 63% completed the collection phase. The patients’ mean (95% CI) CD34+ cell harvest per leukapheresis was 0.8 (0.5–1.4), 0.8 (0.5–1.6) and 1.2 (0.7–2.0)×106 cells/kg for the pegfilgrastim 6 mg, pegfilgrastim 12 mg and filgrastim groups, respectively. Twenty (69%), 17 (59%) and 23 (72%) patients in these three groups achieved the targeted minimum harvest (≥2×106 cells/kg). The mean total harvests were 1.7, 1.4 and 2.2×106 cells/kg, respectively. Post-transplantation, the median days to absolute neutrophil count recovery (≥0.5×109/L) were 12, 11, and 11, respectively. Pegfilgrastim and filgrastim were generally well tolerated. Conclusions Pegfilgrastim (6 or 12 mg) was effective for mobilizing peripheral blood progenitors cells in patients with non-Hodgkin’s lymphoma. These data may aid the design of studies to clarify optimal dosing and leukapheresis with pegfilgrastim.
- 1 March 2008
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 93 (3) , 405-412
Open AccessA phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy
Background Growth factors are frequently used to aid peripheral blood progenitor cell mobilization from bone marrow. This phase 2 study examined the efficacy and safety of pegfilgrastim for mobilizing peripheral blood progenitors cells for autologous transplantation. Design and Methods Patients with non-Hodgkin’s lymphoma received one cycle of mobilizing chemotherapy (ifosfamide, carboplatin and etoposide, ICE). Twenty-four hours later they were randomized, double-blind, to receive a single dose of pegfilgrastim 6 mg or 12 mg, or filgrastim 5 μg/kg/day (until the end of leukapheresis). Following leukapheresis (collection phase), patients rested or received one or two ‘salvage’ cycles of ICE. High-dose BEAM chemotherapy was then given before peripheral blood progenitor cell transplantation. The primary end-point was the patients’ mean yield of CD34+ cells/kg during the collection phase. Results Ninety patients were randomized and received a study drug; 63% completed the collection phase. The patients’ mean (95% CI) CD34+ cell harvest per leukapheresis was 0.8 (0.5–1.4), 0.8 (0.5–1.6) and 1.2 (0.7–2.0)×106 cells/kg for the pegfilgrastim 6 mg, pegfilgrastim 12 mg and filgrastim groups, respectively. Twenty (69%), 17 (59%) and 23 (72%) patients in these three groups achieved the targeted minimum harvest (≥2×106 cells/kg). The mean total harvests were 1.7, 1.4 and 2.2×106 cells/kg, respectively. Post-transplantation, the median days to absolute neutrophil count recovery (≥0.5×109/L) were 12, 11, and 11, respectively. Pegfilgrastim and filgrastim were generally well tolerated. Conclusions Pegfilgrastim (6 or 12 mg) was effective for mobilizing peripheral blood progenitors cells in patients with non-Hodgkin’s lymphoma. These data may aid the design of studies to clarify optimal dosing and leukapheresis with pegfilgrastim.